Prostate cancer is the most frequent malignant non-cutaneous cancer and the second leading cause of cancer-related mortality among men over 50 years old. Hereditary prostate cancer accounts for about 5% to 15% of all cases and is characterized by an early age at onset. First degree relatives of patients with prostate cancer have a 2-5-fold increased risk of developing the condition, depending on the number of affected individuals in the family, indicating the existence of prostate-cancer-susceptibility genes. Prostate cancer susceptibility genes have also been reported in several syndromes associated with tumor growth, including Lynch syndrome and hereditary breast/ovarian cancer. Detection of pathogenic variants in these genes may result in earlier diagnosis and treatment. This test is specifically designed to detect germline pathogenic variants and is not appropriate for the detection of somatic variants in tumor tissue. The panel includes sequence and deletion/duplication analysis of all the listed genes. 

6 weeks
CPT Code 
Test Code 
Test Methods 
Deletion/Duplication analysis
Specimen Types Accepted 
Cultured Cells
Extracted DNA
Additional Information 
If sending saliva, 2 kits are required.
Any gene in the Hereditary Prostate Cancer Panel can also be ordered individually. Please contact us directly for cost and CPT code information.
Variants within exon 15 of the PMS2 gene may not be analyzed or reported due to homology issues. Due to high homology, the sensitivity of this assay may be reduced in exon 2 and exons 12-15 of PMS2.